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Abstract
Background: Therapeutic intervention programs for somatic symptom disorder (SSD) show only small-to-moderate
effect sizes. These effects are partly explained by the motivational problems of SSD patients. Hence, fostering
treatment motivation could increase treatment success. One central aspect in SSD patients might be damage to
motivation because of symptomatic relapses. Consequently, the aim of the present study was to investigate
associations between motivational relapse struggle and therapeutic outcome in SSD patients.
Methods: We assessed 84 inpatients diagnosed with SSD in the early, middle and late stages of their inpatient
treatment. The maintenance subscale of the University of Rhode Island Change Assessment-Short (URICA-S) was
applied as a measure to assess motivational relapse struggle. Additionally, patients completed measures of
treatment outcome that focus on clinical symptoms, stress levels and interpersonal functioning.
Results: The results from multiple regression analyses indicate that higher URICA-S maintenance scores assessed in
early stages of inpatient treatment were related to more negative treatment outcomes in SSD patients.
Conclusions: SSD patients with ambivalent treatment motivation may fail in their struggle against relapse over the
course of therapy. The URICA-S maintenance score assessed at therapy admission facilitated early identification of
SSD patients who are at greater risk of relapse. Future studies should incorporate randomized controlled trials to
investigate whether this subgroup could benefit from motivational interventions that address relapse.
Background
Somatic symptom disorder (SSD) is characterized by
physical symptoms that cannot be fully explained medic-
ally. The prevalence rates of SSD are high, ranging from
5 to 7% of the population [1]. Longitudinal studies have
demonstrated significant chronicity, with up to 90% of
cases lasting longer than 5 years [2, 3]. SSD symptoms
are often associated with severe impairments in the gen-
eral functioning of everyday life, substantial psychosocial
disabilities and diminished quality of life [3, 4]. These pa-
tients show disproportionately elevated rates of medical
care utilization and account for at least 25% of all doctor
visits in primary care [5, 6], leading to high health care
costs [7]. Consequently, psychotherapeutic treatments are
crucial [8]. However, recent meta-analyses have demon-
strated that therapeutic interventions for SSD patients
yield only small-to-moderate effect sizes [7, 8]. Therefore,
a better understanding of individual patient needs is im-
portant, as this could help to develop better treatments
[9]. One core struggle among SSD patients is their highly
ambivalent motivation towards participation in psycho-
logical treatments due to their usually somatically focused
health beliefs [7]. More specifically, patients often search
for the correct medical treatment for their problem [5],
which can negatively impact treatment motivation for psy-
chological interventions [10]. A better understanding of
the motivation to change is thus critical to improving psy-
chotherapeutic treatments for SSD [8].
The transtheoretical model (TTM; [11, 12]) offers a
comprehensive theoretical framework for treatment mo-
tivation and has been investigated empirically in several
studies [13]. The TTM is based on an integrative analysis
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of theories of behavior change from the most influential
therapy schools [11] as well as on empirical studies on
motivational change cycles of self-helpers with different
health behaviors (e.g., smoking cessation) [14]. The model
has been further improved by analyzing treatment motiv-
ation in psychotherapy patients [13], which suggests that
therapeutic interventions should be adapted to match the
motivational stage of the individual patient [11]. Based on
the aforementioned empirical findings, the TTM distin-
guishes five motivational stages of change: In the precon-
templation stage, patients have no desire for therapeutic
change. In the contemplation stage, ambivalence about
therapeutic change is central. In the preparation stage,
there is commitment to therapeutic change. In the action
stage, the focus is on actively working on therapeutic
change, and in the maintenance stage, patients focus on
relapse prevention.
It is of relevance to note that maintenance does not
imply that patients have already passed through psycho-
therapy. Instead, it implies they have relapse struggles
when trying to solve their problems. This applies to both
the time in psychotherapy and the time before entering
psychotherapy [11, 13]. According to the TTM, patients
move through the stages of change in a spiral pattern.
More specifically, this means that relapses are consid-
ered to be integral parts in the change cycle [13]. Recyc-
ling to an earlier stage of change provides patients with
the opportunity to use different, more effective change
strategies [11]. Further, the stages of change are opera-
tionalized using a dimensional approach [11]. This di-
mensional approach conceptualizes the stages of change
as a multidimensional construct in which each patient
has specific values in all the stages of change at the same
measuring time [15]. The most widely applied dimen-
sional measure for assessing the stages of change is the
University of Rhode Island Change Assessment (URICA,
[16, 17]). The URICA consists of 32 items that include eight
items for each of the four subscales, precontemplation,
contemplation, action and maintenance. A meta-analysis
identified a medium effect size of d = .46 to describe the
predictive effects of the stages of change, as measured by
the URICA, on therapeutic outcome [13]. The URICA-S, a
16-item short version with excellent psychometric proper-
ties, has also been validated recently [18, 19]. It should be
noted that the URICA-S maintenance scale includes several
items that characterize struggles with relapse as being a
consequence of ambivalent treatment motivation [18, 20].
Given the lack of empirical evidence on the motivational
change stages in SSD using the URICA-S, research find-
ings from anorexia nervosa (AN) patient groups may pro-
vide ideas about how to investigate the stages of change in
SSD. In AN patients, for instance, the URICA-S mainten-
ance scores at the beginning of treatment were helpful in
identifying patients who experienced less symptom change
across the course of inpatient therapy [21]. Consequently,
the authors concluded that patients with higher scores on
the maintenance domain of the URICA-S could be a sub-
group in need of additional treatment elements to combat
ambivalence and prevent relapse. In fact, initial empirical
evidence suggests that this AN subgroup benefits from
additional treatment components, such as emotion regula-
tion and skills training related to drawbacks, additional
psychoeducation, as well as aftercare programs following
inpatient therapy [22].
These findings from the AN patient groups could po-
tentially apply to SSD patients as well because relapse
struggle is a typical phenomenon in those patients too
[5, 10]. More specifically, many SSD patients have a long
history of medical treatment before entering psychother-
apy [2, 3]. These treatments sometimes result in short-
term success, followed by a relapse of the problems [10].
These mostly unsuccessful attempts to address their prob-
lems before entering psychotherapy can be described in
the spiral pattern of the TTM: some SSD patients try to
resolve their problem (e.g., with medical treatments), have
some short-term success, but then fail to maintain success
and consequently relapse [10, 18]. This can also often be
related to feelings of frustration and, subsequently, to de-
creased motivation in treatment [9]. This subgroup of
SSD patients might need additional treatment compo-
nents, such as interventions pertaining to emotion regula-
tion strategies and skills training related to drawbacks, all
of which could help these individuals cope with their re-
lapse struggle. Therefore, it would be helpful to develop a
stages of change measure that could facilitate the early
identification of SSD patients who are at risk of suffering
from motivational and relapse difficulties. For instance, al-
though the clinical relevance of the Pain Stages of Change
Questionnaire (PSOCQ; [23, 24]), a disorder-specific
stages of change measure for SSD patients, has been
established [10, 25], this measure has no subscale that dir-
ectly assesses relapse struggle (detailed discussion in:
[18]). The PSOCQ maintenance score reflects the ability
to maintain progress [10, 22]. Hence, the URICA-S main-
tenance scale could help identify subgroups of SSD pa-
tients who need special therapeutic attention.
As mentioned above, similar to the initial empirical
evidence obtained in a sample of AN patients [22], SSD
patients with high URICA-S maintenance scores might
need specific treatment elements to address motivational
relapse struggle. As such, the URICA-S maintenance
score could be applied as one component of a relapse
identification tool for SSD patients. More specifically, it
could be applied to the identification of subgroups of
SSD patients who could specifically benefit from motiv-
ational interventions that address relapse. However, we
must first obtain empirical evidence that the URICA-S
maintenance scale can indeed identify SSD patients who
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are at risk of relapse. In this context, future studies
should examine the extent to which therapeutic treat-
ment can be improved using the URICA-S in SSD pa-
tients. The purpose of the current study, therefore, was
to address this research gap. Based on the results of
Mander et al. [21] in AN patients, we hypothesized that
higher maintenance scores in the early, middle and late
stages of therapy would be associated with more nega-
tive treatment outcomes in SSD inpatients. We specific-
ally focused on three different relevant outcomes for
SSD patients: general clinical symptoms, general stress
level and interpersonal functioning.
Method
Treatment and study design
All patients completed an inpatient psychotherapy pro-
gram at the Department of Psychosomatic Medicine and
Psychotherapy of Tuebingen University, Germany. The
treatment consisted of individual therapy, group therapy,
art therapy and music therapy twice per week. Psycho-
therapy incorporated a cognitive-behavioral approach
with supplementary interpersonal psychotherapeutic ele-
ments. Eighteen psychotherapists (15 female) with at
least 1 year of experience conducted therapy. Individual
therapy was conducted two times per week. Inpatient
treatment ranged from a minimum of 14 days to a max-
imum of 64 days, with a mean of 38.1 (SD 14.2) days.
Patients were assessed at baseline (t1), after the 8th
session (t2) and after the last session (t3). Treatment mo-
tivation was assessed at all three time points using the
URICA-S [16, 18]. Clinical outcome measures were
administered at baseline and after treatment. More spe-
cifically, at t1 and t3, patients completed the Symptom-
Checklist-90-Revised (SCL-90-R; [26]), Perceived Stress
Questionnaire (PSQ; [27]), and Inventory of Interpersonal
Problems (IIP; [28]). Additionally, the Structured Clinical
Interview, German version (SCID-I, [29, 30]), was admin-
istered to all patients at baseline. The initial SCID-I assess-
ment was conducted by one of two PhD-students who
had previously completed a university-based SCID train-
ing. A university-affiliated expert regularly supervised
these students. The local ethics committee of the medical
faculty at the University of Tuebingen approved the study
protocol (project number 29/2009B02) in compliance with
the Helsinki Declaration. All participants provided written
informed consent prior to study participation.
Subjects
Eighty-four inpatients being treated for SSD participated in
the study. To be included, subjects had to have received an
SCID-I primary diagnosis of a full syndrome of SSD. The
general exclusion criteria were as follows: (1) patient age
younger than 18 years or older than 59 years, (2) insufficient
German language skills, (3) psychotic or substance-related
disorders as comorbidities, and (4) current suicidal risk. Be-
cause we intended to investigate a naturalistic sample, co-
morbidities with mental disorders not on the exclusion list
were not considered to be exclusions for study participation
if SSD was the main treatment diagnosis. Overall, the study
sample was 71.4% female. The average age of participants
was 48.0 years (SD 11.9), while 59.5% were married/with
partner, 19% had an A-level degree and 88.2% had a formal
professional qualification. Furthermore, 50.0% were
employed, 4.8% were still in job training, 25% were retired
and 20.2% were unemployed. The sample included 59.5%
with a diagnosis of major depression (36.9% single episode,
22.6% recurrent depression) and 10.7% with an anxiety dis-
order (9.5% panic disorder and agoraphobia; 1.2% specific
phobia) as a comorbidity. According to patient interviews
and medical data, all patients suffered from SSD symptoms
for several years.
Measures
URICA-S
The URICA-S [18] is a short version of the URICA [16].
The URICA-S consists of 16 items that are rated on a scale
from 0 (does not apply) to 4 (fully applies) and measures
four stages of change (precontemplation, contemplation,
action, maintenance) with 4 items per subscale (items
listed in the appendix). In a sample of 253 patients, Man-
der et al. [18] demonstrated an excellent factor structure
with factor loadings of .52 ≤ λ ≤ .87. Confirmatory factor
analyses supported the exploratory model. The instrument
yielded acceptable-to-excellent internal consistencies, with
.61 ≤ α ≤ .84, along with high correlations with the sub-
scales of the original long-form URICA, with .83 ≤ r ≤ .96.
The contemplation, action and maintenance subscales and
committed action global score significantly predicted thera-
peutic outcome. The maintenance score from the URICA-S
specifically refers to the struggle with relapse, with stronger
negative values indicative of more problems with relapse.
Hence, it might be especially important to identify patients
at risk of further chronicity. All items of the URICA-S are
listed in the online supplement Additional file 1.
SCL-90-R
The SCL-90-R [26, 31] is a measure of general symptom
severity. It consists of eleven subscales totaling 90 items
rated along a 5-point scale. The measure has demon-
strated excellent internal consistencies, with .79 ≤ α ≤ .89,
and good retest-reliabilities, with .69 ≤ r ≤ .92. Acceptable
construct validity has also been reported, with scale-
outcome correlations between .27 ≤ r ≤ .81.
PSQ
The PSQ [27, 32] is a 30-item scale that was designed to
evaluate the stress level of a patient within the seven
factors of harassment, overload, irritability, lack of joy,
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fatigue, worries, and tension. Each item is rated along a
5-point scale. The PSQ has demonstrated excellent
psychometric properties, with internal consistencies of
.80 ≤ α ≤ .86, as well as convergent validity via correlations
of .56 ≤ r ≤ .73 with other instruments referring to stress,
anxiety, and depression. It has further demonstrated sensi-
tivity to change across the course of therapy.
IIP
The IIP is a 64-item instrument that utilizes a circumplex
structure to assess interpersonal problems [28, 33, 34] . Its
eight scales include domineering, intrusive, overly nurtur-
ant, exploitable, nonassertive, socially avoidant, cold, and
vindictive, rated on a 5-step scale. The IIP has shown ex-
cellent psychometric properties, with .75 ≤ α ≤ .94, and
criterion validity has been demonstrated through correla-
tions with the SCL-90-R, with .07 ≤ r ≤ .75.
Statistical analyses
To identify empirical associations between the stages of
change and therapeutic outcomes, we initially calculated a
set of correlation analyses, computing separate analyses
for each of the three therapeutic outcome measures. More
specifically, we correlated the URICA-S subscales with the
SCL-90-R, PSQ, and IIP global scores in separate analyses.
In the next step, we calculated a set of hierarchical regres-
sion analyses, computing separate regression analyses for
each of the three therapeutic outcome measures as the
dependent variable. More specifically, we analyzed one re-
gression model with the SCL-90-R global score at t3, one
with the PSQ global score at t3 and one with the IIP global
score at t3 as the dependent variable. In each model, we
blockwise entered the four URICA-S subscale scores as
well as the baseline score of the relevant outcome measure
as predictors. In the first block, we entered the global
score of the relevant outcome measure at baseline as an
autoregressor. In the second block, we always entered
the maintenance score because it demonstrated the
strongest association with the therapeutic outcome in
the correlation analyses. The order in which the other
subscales were entered in subsequent blocks depended
on the strengths of their correlations with the out-
come measures.
Results
Correlation analyses of the URICA-S revealed the fol-
lowing results for the stages of change subscales: Precon-
templation was not significantly associated with any of
the therapeutic outcome scores. Contemplation at t1 was
significantly associated with the PSQ, but no other sig-
nificant associations emerged for contemplation. Action
was not significantly associated with any of the thera-
peutic outcome scores. Maintenance was significantly
associated with all three outcome measures (the SCL-
90-R, the PSQ and the IIP) at all three measuring times.
The results of the correlation analyses are depicted in
Table 1.
In the multiple regression analyses, only maintenance
proved to be a significant predictor of outcome when
controlling for the baseline outcome scores.
Concerning SCL-90-R, maintenance at t1 was a signifi-
cant predictor of SCL-90-R at t3 while controlling for
SCL-90-R at t1, ΔR
2 = .08, p = .005. Maintenance at t2
and t3 did not significantly predict SCL-90-R at t3. How-
ever, trends (p < .10) were observable, with ΔR2 = .05.
p = .065 for maintenance at t2 and ΔR
2 = .022, p = .069
for maintenance at t3.
Concerning the PSQ, maintenance was a significant
predictor at all three measuring times. More specifically,
the maintenance score was a significant predictor of the
PSQ at t3 while controlling for the PSQ at t1; with
ΔR2 = .08, p < .001 for maintenance at t1; ΔR
2 = .06,
p = .022 for maintenance at t2; and ΔR
2 = .07, p = .017
for maintenance at t3.
Concerning the IIP, maintenance at t1 and t2 were sig-
nificant predictors. More specifically, the maintenance
score was a significant predictor of the IIP at t3 while
controlling for the IIP at t1, with ΔR
2 = .02, p = .023 for
maintenance at t1; and with ΔR
2 = .03, p = .034 for
maintenance at t2. Maintenance at t3 was not a signifi-
cant predictor of the IIP at t3. However, a trend (p < .10)
was observable, with ΔR2 = .02, p = .087.
None of the other stages of change proved to be a sig-
nificant predictor in any regression model. For parsimo-
nious reasons, we only report the significant regression
models in Tables 2, 3 and 4.
Table 1 Correlations of the URICA subscales at all three measuring
times with SCL, PSQ and IIP at the end of therapy
Precontemplation Contemplation Action Maintenance
SCL-90-R
t1 .11 .15 .03 .48
**
t2 .13 .12 −.07 .38
**
t3 .00 .22 −.04 .43
**
PSQ
t1 .08 .28
* .19 .48**
t2 .02 −.05 −.34 .34
**
t3 .15 .17 −.03 .38
**
IIP
t1 .11 .18 .06 .42
**
t2 .07 .00 −.04 .32
*
t3 −.04 .09 −.14 .30
*
t1/t2/t3 = at baseline/8th/last therapy session
SCL-90-R Symptom-Checklist-90-Revised, PSQ Perceived Stress Questionnaire,
IIP Inventory of Interpersonal Problems
* = p < .05; ** = p < .01
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Discussion
SSD patients show disproportionately elevated rates of
medical care utilization, leading to high health care costs
[7]. Further, therapeutic intervention programs for SSD
patients show only small-to-moderate effect sizes [7, 8].
This is partly explained by the ambivalent motivation of
SSD patients to receive psychological treatments [10].
Hence, fostering treatment motivation could increase
treatment success in this patient group [8]. The aim of
the present study was to investigate associations between
the TTM stages of change and general symptomatology
and general stress level, as well as interpersonal
functioning in SSD patients. We specifically hypothe-
sized that higher scores on the URICA-S maintenance
scale, as an indicator of motivational relapse struggle,
would be associated with more negative treatment out-
comes in SSD inpatients. Of note, our results indicate
that URICA-S maintenance at the first measuring time
was a significant predictor of all three outcome mea-
sures. This applied to both the correlation analyses and
longitudinal multiple regression analyses controlling for
baseline symptom severity. These findings indicate that
the higher the maintenance score at the beginning of
therapy, that is, the greater the struggle with relapse, the
Table 2 Significant linear regression coefficients of stages of change predicting SCL-90 symptomatology at the end of therapy
95% CI
B SE B β t p Lower bound Upper bound R2
Model 1: Maintenance t1 .57
Constant .31 .15 2.11 .039 .02 .61
SCL-90 baseline .26 .08 .36 3.31 <.001 .10 .42
Maintenance t1 .23 .08 .32 2.92 .005 .07 .38
Model 2: Maintenance t2 .53
Constant .36 .16 2.27 .027 .04 .69
SCL-90 baseline .25 .07 .42 3.50 <.001 .11 .39
Maintenance t2 .15 .08 .23 1.89 .065 −.01 .31
Model 3: Maintenance t3 .70
Constant −.18 .13 −1.33 .191 −.45 .09
SCL-90 baseline .84 .09 .77 9.14 <.001 .66 1.03
Maintenance t3 .10 .05 .16 1.90 .069 −.01 .21
t1/t2/t3 = at baseline/after 8th therapy session/ end of therapy. Model 1 / Model 2 / Model 3 = significant stages of change predictors at baseline/8th/last therapy
session for SCL-90 at the end of therapy.
SCL-90-R Symptom-Checklist-90-Revised
Table 3 Significant linear regression coefficients of stages of change predicting PSQ symptomatology at the end of therapy
95% CI
B SE B β t p Lower bound Upper bound R2
Model 1: Maintenance t1 .49
Constant .06 .06 .92 .362 −.07 .18
PSQ baseline .61 .11 .52 5.68 <.001 .40 .83
Maintenance t1 .05 .02 .31 3.33 <.001 .02 .08
Model 2: Maintenance t2 .43
Constant .03 .07 .33 .74 −.12 .17
PSQ baseline .67 .12 .57 5.60 <.001 .43 .91
Maintenance t2 .04 .02 .24 2.35 .022 .006 .08
Model 3: Maintenance t3 .42
Constant .02 .08 .26 .79 −.15 .19
PSQ baseline .67 .14 .54 4.94 <.001 .40 .95
Maintenance t3 .04 .02 .27 2.46 .017 .01 .08
t1/t2/t3 = at baseline/after 8th therapy session/ end of therapy. Model 1 / Model 2 / Model 3 = significant stages of change predictors at baseline/8th/last therapy
session for PSQ at the end of therapy.
PSQ Perceived Stress Questionnaire
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lower the change in the three outcome measures across
the course of therapy. This is clinically relevant, as it in-
dicates that assessment of the patients´ maintenance
stage of change at the beginning of therapy can help
identify patients who will be more likely to have negative
treatment outcomes. Furthermore, URICA-S mainten-
ance at therapy admission significantly predicted pa-
tients’ general clinical symptoms, general stress levels
and interpersonal functioning. Consequently, the results
indicate that URICA-S maintenance, as assessed early in
treatment, is an important predictor of three essential
aspects of the general functioning of SSD patients.
However, an important limitation of our results is that
maintenance assessed at t2 and t3 did not significantly
predict general symptom severity as assessed by the
SCL-90-R or interpersonal functioning as assessed by
the IIP. Here, only trends (p < .10) toward predictive ef-
fects were observable. These effects could possibly reach
significance with more statistical power in larger SSD
samples. However, identifying this aspect empirically re-
mains a task for future research. Hence, given our
current research results, it remains unclear whether
maintenance assessed later in therapy is still a relevant
predictor of the therapeutic outcome. Consequently, our
results must be regarded as preliminary and should be
interpreted with caution. Further, and similar to our pre-
vious findings in AN patients [21], no other stages of
change were significant predictors of outcome.
Hence, in SSD patients, the maintenance score
assessed at therapy admission seems to be an indicator
of the relapse threat, which could be helpful for early
identification of inpatients who could improve during
therapy as well as those who might suffer from repeated
drawbacks. In many SSD patients, the course of their dis-
order is characterized by high chronicity and recurrent re-
lapses, while the first months after inpatient treatment
seem to represent a highly vulnerable phase [7, 8]. Conse-
quently, should our results be replicated in future studies,
the URICA-S maintenance ratings could be used to sup-
plement the clinical judgments of expert diagnosticians to
identify high-risk patient subgroups that need further
treatment elements in addition to routine therapy. More
specifically, similar to preliminary studies in AN patients
[22], these patient subgroups could receive a specific treat-
ment to address ambivalence, skills training related to
drawbacks, and additional psychoeducation as well as
aftercare programs following inpatient treatment.
As mentioned previously, the PSOCQ can also be a
disorder-specific stage of change measure for SSD pa-
tients, and several studies have documented its clinical
utility (e.g. [10, 24]). Future research should use the
PSOCQ to examine the extent to which our current
study results can be replicated with a disorder-specific
measure. In contrast to the URICA-S, where mainten-
ance refers to relapse struggle, the PSOCQ maintenance
scale reflects the ability to maintain progress [23, 24].
The current study results indicate that a relapse measure
is important in SSD research, as high chronicity and re-
current relapses are important characteristics of the dis-
order [7, 8]. Consequently, it might be of interest to
devise a new, more differentiated disorder-specific main-
tenance scale for the PSOCQ that contains a progress
maintenance component and relapse facet.
The current study has the following limitations: First,
our study was conducted in an inpatient setting. Hence,
the generalizability of the effects to other treatment
Table 4 Significant linear regression coefficients of stages of change predicting IIP symptomatology at the end of therapy
95% CI
B SE B β t p Lower bound Upper bound R2
Model 1: Maintenance t1 .68
Constant .08 .12 .71 .48 −.15 .32
IIP baseline .85 .08 .75 10.53 <.001 .69 1.01
Maintenance t1 .09 .04 .17 2.33 .023 .01 .17
Model 2: Maintenance t2 .66
Constant .00 .15 .01 .996 −.30 .30
IIP baseline .88 .09 .76 9.67 <.001 .70 1.07
Maintenance t2 .09 .04 .17 2.18 .034 .01 .18
Model 3: Maintenance t3 .64
Constant .11 .16 .68 .501 −.21 .43
IIP baseline .86 .10 .76 8.78 <.001 .66 1.05
Maintenance t3 .07 .04 .15 1.75 .087 −.01 .16
t1/t2/t3 = at baseline/after 8th therapy session/ end of therapy. Model 1 / Model 2 / Model 3 = significant stages of change predictors at baseline/8th/last therapy
session for IIP at the end of therapy.
IIP Inventory of Interpersonal Problems
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setting remains unclear and should be addressed in fu-
ture studies. Second, we conducted a naturalistic study
without a control group. Future research should try to
directly implement motivational interventions to im-
prove the outcomes of patients who score high for
URICA-S maintenance at the beginning of therapy. Con-
sequently, a randomized controlled design, such as one
that incorporates motivational interviewing [35] in the
experimental condition and typical treatment in the con-
trol condition, should be applied. Third, two predictors
in regression analyses were only marginally significant.
Hence, our results should be interpreted with caution.
However, when interpreting the results, not only should
the specific effect of the single predictor be recognized
but the whole pattern of results should be interpreted.
More specifically, maintenance was a significant pre-
dictor of therapeutic outcome irrespective of measuring
time and whether general clinical symptoms, the general
stress level or interpersonal functioning were entered as
dependent variables. Consequently, maintenance seems
to be one important aspect that should be addressed to
increase the chance of successful psychotherapy. Fourth,
in the current study, approximately 60% of patients suf-
fered from comorbid depressive disorders. SSD patients
with and without depression might show different pat-
terns regarding the effects of treatment motivation on
the therapeutic outcome. In our study, the statistical
power to identify subgroup effects of SSD patients with
and without comorbidities was too low. Hence, future
studies should investigate this aspect in more adequately
powered subsamples. Finally, future studies should investi-
gate associations between motivation and outcome on a
session-to-session basis, as this could capture greater vari-
ations and nuances within the therapeutic process.
Conclusions
In conclusion, the present study analyzed associations
between the stages of change assessed with the URICA-
S and therapeutic outcome in SSD patients. The
URICA-S maintenance score assessed at the beginning
of therapy could be used to help identify SSD patients
who have a relapse risk. Future studies should incorpor-
ate randomized controlled trials to investigate whether
this subgroup could benefit from motivational interven-
tions to address relapse.
Additional file
Additional file 1: Items_of_the_URICA-S, the additional file includes all
items of the URICA-S scale. (DOCX 12 kb)
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